QIAGEN NV Stock
Pros and Cons of QIAGEN NV in the next few years
Pros
Cons
Performance of QIAGEN NV vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| QIAGEN NV | - | - | - | - | - | - | - |
| Ironwood Pharmaceuticals | 0.690% | - | - | - | - | - | - |
| Sage Therapeutics Inc. | -1.020% | 7.851% | -25.000% | -69.792% | -34.750% | -79.867% | - |
| Novocure Ltd | -2.010% | 1.864% | -20.671% | -80.817% | -19.615% | -93.244% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.QIAGEN, a leading company in the Biotechnology & Medical Research industry, appears to exhibit a healthy financial performance based on the data provided. The company's assets, revenues, and net income have steadily increased over the past three years, which may indicate a solid financial foundation and growth potential.
Increasing Total Assets: QIAGEN's total assets grew from approximately $5.97 billion in 2020 to about $6.29 billion in 2022, representing a consistent year-over-year growth pattern. This indicates the company's ability to expand its business and maintain a strong asset base.
Rising Revenue: The total revenue generated by QIAGEN has shown an upward trend from $1.87 billion in 2020 to nearly $2.14 billion in 2022. Steady revenue growth is a positive sign for investors and suggests that the company is effectively managing its operations.
Comments
News
EQS-Adhoc: QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
